Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study.

Autor: Meenks SD; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands. sjoerd.meenks@mumc.nl.; Department of Clinical Pharmacy, Catharina Hospital Eindhoven, P.O. Box 1350, 5602 ZA, Eindhoven, The Netherlands. sjoerd.meenks@mumc.nl.; Department of Hospital Pharmacy, VieCuri Medical Center, 5900 BX, Venlo, The Netherlands. sjoerd.meenks@mumc.nl., Punt N; Medimatics, 6229 HR, Maastricht, The Netherlands.; University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands., le Noble JLML; Department of Intensive Care, VieCuri Medical Center, 5900 BX, Venlo, The Netherlands.; Department of Pharmacology and Toxicology, P.O. Box 616, 6200 MD, Maastricht, The Netherlands., Foudraine NA; Department of Intensive Care, VieCuri Medical Center, 5900 BX, Venlo, The Netherlands., Neef K; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.; Department of Pharmacology and Toxicology, P.O. Box 616, 6200 MD, Maastricht, The Netherlands., Janssen PKC; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.; Department of Hospital Pharmacy, VieCuri Medical Center, 5900 BX, Venlo, The Netherlands.
Jazyk: angličtina
Zdroj: Critical care (London, England) [Crit Care] 2023 Mar 03; Vol. 27 (1), pp. 82. Date of Electronic Publication: 2023 Mar 03.
DOI: 10.1186/s13054-023-04353-5
Abstrakt: Purpose: Insufficient antimicrobial exposure has been associated with worse clinical outcomes. Reportedly, flucloxacillin target attainment in critically ill patients was heterogeneous considering the study population selection and reported target attainment percentages. Therefore, we assessed flucloxacillin population pharmacokinetics (PK) and target attainment in critically ill patients.
Methods: This prospective, multicenter, observational study was conducted from May 2017 to October 2019 and included adult, critically ill patients administered flucloxacillin intravenously. Patients with renal replacement therapy or liver cirrhosis were excluded. We developed and qualified an integrated PK model for total and unbound serum flucloxacillin concentrations. Monte Carlo dosing simulations were performed to assess target attainment. The unbound target serum concentration was four times the minimum inhibitory concentration (MIC) for ≥ 50% of the dosing interval (ƒT >4xMIC  ≥ 50%).
Results: We analyzed 163 blood samples from 31 patients. A one-compartment model with linear plasma protein binding was selected as most appropriate. Dosing simulations revealed 26% ƒT >2 mg/L  ≥ 50% following continuous infusion of 12 g flucloxacillin and 51% ƒT >2 mg/L  ≥ 50% for 24 g.
Conclusion: Based on our dosing simulations, standard flucloxacillin daily doses of up to 12 g may substantially enhance the risk of underdosing in critically ill patients. Prospective validation of these model predictions is needed.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: